Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 Read more about Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies Read more about Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting Read more about Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference Read more about Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
Xencor Reports Second Quarter 2021 Financial Results Read more about Xencor Reports Second Quarter 2021 Financial Results
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021 Read more about Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
Xencor to Present at the Jefferies Virtual Healthcare Conference Read more about Xencor to Present at the Jefferies Virtual Healthcare Conference
Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 Read more about Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19 Read more about Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
